Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses

被引:35
作者
Amiche, M. Amine [1 ,2 ]
Levesque, Linda E. [1 ,2 ]
Gomes, Tara [1 ,2 ,3 ]
Adachi, Jonathan D. [4 ]
Cadarette, Suzanne M. [1 ,2 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON M5S 3M2, Canada
[2] Inst Clin Evaluat Sci, Toronto, ON, Canada
[3] St Michaels Hosp, Toronto, ON, Canada
[4] McMaster Univ, Dept Med, Hamilton, ON, Canada
关键词
BISPHOSPHONATES; GLUCOCORTICOID; FRACTURE RISK; EFFECTIVENESS; OSTEOPOROSIS; CORTICOSTEROID-INDUCED OSTEOPOROSIS; BONE-MINERAL DENSITY; HEALTH ADMINISTRATIVE DATABASES; DOUBLE-BLIND; VERTEBRAL FRACTURE; ETIDRONATE THERAPY; CONTROLLED-TRIAL; ZOLEDRONIC ACID; RISEDRONATE; MANAGEMENT;
D O I
10.1002/jbmr.3318
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The benefit of oral bisphosphonates in reducing fracture risk in glucocorticoid-induced osteoporosis is controversial. We aimed to estimate the effectiveness of oral bisphosphonates in reducing fracture risk in a cohort of new chronic oral glucocorticoid users. We created three matched cohorts using health care administrative data from Ontario, Canada. We included residents aged 66 years and older initiating chronic oral glucocorticoids (450mg prednisone equivalent and 2 glucocorticoid prescriptions within a 6-month window) between January 1998 and September 2014. Exposed patients were those who initiated an oral bisphosphonate (alendronate, etidronate, or risedronate) within the first 6 months of starting chronic oral glucocorticoid therapy. Exposed cohorts (3945 alendronate, 5825 risedronate, and 8464 etidronate) were each matched 1:1 to unexposed patients on glucocorticoid exposure, fracture risk factors, and propensity score. We examined incident hip (primary outcome), vertebral, forearm, and humerus fractures using Cox proportional hazard models. Alendronate (hazard ratio [HR]=0.46, 95% confidence interval [CI] 0.25-0.80) and risedronate (HR=0.58, 95% CI 0.36-0.90) were associated with reduced hip fracture risk. Alendronate (HR= 0.52, 95% CI 0.39-0.68), etidronate (HR=0.59, 95% CI 0.48-0.73) and risedronate (HR=0.47 95% CI 0.36-0.60) were associated with reduced vertebral fracture risk. No risk reduction in forearm or humerus fractures was apparent for any bisphosphonate. Among older chronic glucocorticoid initiators, all oral bisphosphonates reduced vertebral fracture risk, yet only alendronate and risedronate reduced hip fracture risk. Results were similar between men and women. We provided compelling evidence that early initiation of oral bisphosphonates during chronic oral glucocorticoid therapy is beneficial to prevent osteoporotic fractures. (c) 2017 American Society for Bone and Mineral Research.
引用
收藏
页码:419 / 429
页数:11
相关论文
共 45 条
[1]  
Adachi JD, 1996, J RHEUMATOL, V23, P995
[2]   Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[3]  
Adachi JD, 2001, ARTHRITIS RHEUM-US, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO
[4]  
2-W
[5]   Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012 [J].
Albaum, J. M. ;
Levesque, L. E. ;
Gershon, A. S. ;
Liu, G. ;
Cadarette, S. M. .
OSTEOPOROSIS INTERNATIONAL, 2015, 26 (12) :2845-2852
[6]  
Albaum JM, 2014, J POPUL THER CLIN PH, V21, pE486
[7]   Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis [J].
Amiche, M. A. ;
Albaum, J. M. ;
Tadrous, M. ;
Pechlivanoglou, P. ;
Levesque, L. E. ;
Adachi, J. D. ;
Cadarette, S. M. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (06) :1989-1998
[8]   Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials [J].
Amiche, M. A. ;
Albaum, J. M. ;
Tadrous, M. ;
Pechlivanoglou, P. ;
Levesque, L. E. ;
Adachi, J. D. ;
Cadarette, S. M. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (05) :1709-1718
[9]   Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies [J].
Austin, Peter C. .
PHARMACEUTICAL STATISTICS, 2011, 10 (02) :150-161
[10]   Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone [J].
Axelsson, Kristian F. ;
Nilsson, Anna G. ;
Wedel, Hans ;
Lundh, Dan ;
Lorentzon, Mattias .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (02) :146-155